10-Q: International Stem Cell Corporation Reports Third Quarter 2024 Results, Cites Ongoing Going Concern Uncertainty

International Stem Cell Corporation's Q3 2024 results show increased product sales but continued net losses and concerns about the company's ability to continue as a going concern.

Summary

• International Stem Cell Corporation reported a net loss of $220 thousand for the nine months ended September 30, 2024, compared to a net income of $327 thousand for the same period in 2023.
• Product sales increased to $6.639 million for the nine months ended September 30, 2024, up from $5.9 million in the same period of 2023, driven primarily by growth in the biomedical market segment.
• The company's operating expenses totaled $6.758 million for the nine months ended September 30, 2024, compared to $6.139 million for the same period in 2023.
• The company had an accumulated deficit of approximately $110.7 million as of September 30, 2024, and has historically incurred net losses.
• The company's cash balance was $1.307 million as of September 30, 2024, down from $1.588 million at the end of 2023.
• The company has stated that it needs to obtain additional financing to sustain operations for at least twelve months from the issuance date of these financial statements.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.

Sentiment

Score: 3

Explanation: The document highlights a concerning financial situation with a net loss, decreasing cash balance, and a going concern warning, despite some positive revenue growth. The need for additional financing and the uncertainty surrounding the company's future significantly weigh down the sentiment.

Positives

• Product sales increased by 10% in the three months ended September 30, 2024, and 13% for the nine months ended September 30, 2024, indicating growth in the company's commercial operations.
• The biomedical market segment experienced strong growth, particularly in media product sales.
• The company is actively managing its cash flow and exploring various financing options.

Negatives

• The company reported a net loss of $220 thousand for the nine months ended September 30, 2024, compared to a net income of $327 thousand for the same period in 2023.
• The company has an accumulated deficit of approximately $110.7 million as of September 30, 2024.
• The company's cash balance decreased to $1.307 million as of September 30, 2024, from $1.588 million at the end of 2023.
• The company has stated that it needs to obtain additional financing to sustain operations for at least twelve months from the issuance date of these financial statements.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing or extending the maturity of existing financing.
• The company has historically incurred net losses and does not generate sufficient cash flow from operating activities to fund operations.
• The company's research and development programs are long-term investments that may not generate revenue in the near future.
• The company's dependence on a few key customers could pose a risk if those relationships were to change.
• The company's debt financing may be expensive and require pledging a substantial portion of its assets.
• The company may be required to relinquish rights to some of its technologies or products if additional funds are obtained through collaborative partners.
• The company's failure to raise capital or enter into related arrangements when needed would have a negative impact on its financial condition.

Future Outlook

The company's future is dependent on obtaining additional financing or extending the maturity of existing financing to sustain operations and develop products. The timing and degree of future capital requirements will depend on various factors, including the progress of research and development programs, clinical trials, and regulatory approvals.

Management Comments

• Management continues to evaluate various financing sources and options to raise working capital to help fund our current research and development programs and operations.
• Management's plans in regard to these matters are focused on managing our cash flow, the proper timing of our capital expenditures, and raising additional capital or financing in the future.

Industry Context

The company operates in the biotechnology industry, which is characterized by high research and development costs, long development timelines, and regulatory hurdles. The company's focus on stem cell therapies places it in a competitive landscape with other companies developing similar treatments. The company's commercial businesses in skin care and cell culture products provide some revenue diversification but are not sufficient to offset the losses from the therapeutic development programs.

Comparison to Industry Standards

• The company's revenue growth of 13% year-over-year is a positive sign, but it is important to compare this to the growth rates of other companies in the biotechnology and life sciences sectors.
• The company's net loss of $220 thousand for the nine months ended September 30, 2024, compared to a net income of $327 thousand for the same period in 2023, is a significant concern and should be compared to the profitability of similar companies.
• The company's cash balance of $1.307 million as of September 30, 2024, is relatively low and should be compared to the cash reserves of other companies in the industry, especially those with similar research and development programs.
• The company's statement about its ability to continue as a going concern is a serious issue and should be compared to the financial stability of other companies in the sector.
• Companies like Geron Corporation (GERN) and BioTime (now Lineage Cell Therapeutics, LCTX) are also involved in stem cell research and development, and their financial performance and cash positions could be used as benchmarks.
• The company's reliance on a few key customers is a risk that should be compared to the customer diversification of other companies in the industry.

Related Party Transactions

• The company has a lease agreement with S Real Estate Holdings, LLC, a related party, for its corporate headquarters.
• The company has a related party note payable to Dr. Semechkin, which was amended during the quarter.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and need for additional financing.
• Employees may be concerned about job security given the company's financial challenges.
• Customers of the company's biomedical and anti-aging products may be impacted if the company's financial situation affects its ability to operate.
• Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

• The company plans to obtain significant additional funding from sources, including through debt and equity financing, license arrangements, grants and/or collaborative research arrangements to sustain its operations and develop products.
• The company will continue to monitor the probability of the contingency event related to the Series D redeemable convertible preferred stock at each reporting date.
• The company is planning to identify and relocate to larger facilities upon the end of the original term date of December 2025 for its Frederick, Maryland lease.

Key Dates

Keywords

stem cells, biotechnology, clinical trials, Parkinson's disease, neural stem cells, skin care, cell culture, research and development, financing, going concern